Balance sheet as of December 31, 2009

Profit and loss account – Year ended December 31, 2009

Introduction

In 2009, Alzheimer Europe had an audited income of EUR 692,894.74 of which EUR 350,510.24 (50.59%) were for the organisation’s core activities (including the organisation’s Dementia Ethics Network and Annual Conference) and EUR 342,384.50 (49.41%) were for the organisation’s public affairs activities.

Funding of core activities (EUR 350,510.24)

In 2009, the core funding of Alzheimer Europe was composed as follows:

• EUR 150,371.28 (42.90%) from member organisations,
• EUR 89,905.33 (25.65%) from individuals,
• EUR 51,222.21 (14.61%) from public funding,
• EUR 36,750 (10.48%) from corporate sources,
• EUR 15,000 (4.28%) from foundations and other non-profit organisations,
• EUR 6,117.15 (1.75%) from other sources and
• EUR 1,144.27 (0.33%) from bank interest and similar.

Funding from member organisations

In 2009, the EUR 150,371.28 funding from member organisations can be broken down as follows:

• EUR 91,107.31 in co-financing from the Luxembourg member organisation through the secondment of the AE Executive Director,
• EUR 46,500 in membership fees,
• EUR 12,000 in co-financing from the Luxembourg member organisation by providing the offices of Alzheimer Europe free of rent,
• EUR 763.97 in co-financing from member organisations covering the travel expenses of AE Board members to attend Board meetings.

Individuals

In 2009, AE received EUR 89,905.33 from individuals which can be broken down as follows:

• EUR 86,875 in conference registrations,
• EUR 2,572.33 in publication sales and
• EUR 458 in donations.

Public funding

In 2009, Alzheimer Europe received EUR 51,222.21 from the German Ministry of Health to cover the expenditure for the setting up of the European Dementia Ethics Network.

In 2009, Alzheimer Europe did not receive funding from the European Commission or other European agencies.

Corporate support

In 2009, Alzheimer Europe received EUR 36,750 from corporate sources as core-funding which can be broken down as follows:

• EUR 10,000 from Janssen-Cilag and Pfizer as support to the Alzheimer Europe Conference in Brussels,
• EUR 5,000 from Lundbeck and Multimount as support to the Alzheimer Europe Conference in Brussels,
• EUR 3,750 from Wyeth as support to the Alzheimer Europe Conference in Brussels,
• EUR 3,000 as co-financing from Mazars which carried out the audit of the organisation’s accounts free of charge.

Foundations and organisations

The EUR 15,000 which Alzheimer Europe received in 2009 from foundations and other non-profit organisations can be broken down as follows:

• EUR 5,000 from Fondation Médéric Alzheimer, Fondation Roi Baudouin and EUR Mutualités libres to support the Alzheimer Europe Conference in Brussels,

Bank interest and similar

In 2009, Alzheimer Europe had an income of EUR 1,144.27 from bank interest and similar income.

Other income

In 2009, EUR 6,117.15 came from other sources not mentioned above.

Funding of public affairs activities (EUR 342,384.50)

In 2009, Alzheimer Europe received EUR 342,384.50 for its public affairs activities, of which

• EUR 239,107.68 (69.83%) came from corporate sponsors,
• EUR 83,798.13 (23%) from reserves brought forward from the financial year 2008,
• EUR 9,000 from foundations and organisations,
• EUR 1,591.98 from member organisations and
• EUR 8,886.71 from other sources.

Corporate support

The corporate support received by Alzheimer Europe for its public affairs activities can be broken down as follows:

• Pfizer contributed EUR 40,000 as a gold sponsor and EUR 826.20 in travel support,
• Novartis contributed EUR 40,000 as a gold sponsor and EUR 294.95 in travel support
• Janssen-Cilag contributed EUR 40,000 as a gold sponsor,
• GlaxoSmithKline contributed EUR 35,287.80 as a gold sponsor and EUR 1,027.76 in travel support and honoraria,
• Lundbeck contributed EUR 20,000 as a silver sponsor and EUR 2,152.40 in travel support and honoraria,
• Lilly contributed EUR 20,000 as a silver sponsor and EUR 2,000 in travel support and honoraria,
• Wyeth contributed EUR 20,000 as a silver sponsor,
• Elan contributed EUR 9,263.44 as a bronze sponsor,
• Sudler & Hennessy contributed EUR 6,761.35 in travel support and honoraria,
• Huntsworth Health contributed EUR 1,143.46 in travel support and honoraria,
• Bayer contributed EUR 178 in travel support,
• Alzheimer Europe received a donation of EUR 172.32 from Mark Krueger and Associates.

Reserves

In 2009, Alzheimer Europe was able to contribute EUR 83,798.13 of its own reserves to its public affairs activities which came from income received on account in 2008.

Foundations and organisations

In 2009, Alzheimer Europe received EUR 9,000 from Fondation Médéric Alzheimer for the work carried out on the inventory of national legislation on healthcare decision making and the publication of its 2009 Dementia in Europe Yearbook.

Member organisations

Members contributed EUR 1,591.98 in 2009 in co-financing for travel expenditure incurred by member organisations for public affairs meetings organised by AE.

Other income

In 2009, EUR 8.886.71 came from sources not included above.

Overall funding

The following table lists all sources of income received in 2009. In line with the policy of the European Medicines Agency on transparency requirements for accredited patients’ organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.